Shares of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) are trending Friday morning, continuing a momentum surge that recently pushed the biotech stock to a new 52-week high after gaining over 250% year-to-date.
Iovance Biotherapeutics stock is building positive momentum. Why is IOVA stock advancing?
Spillover Sentiment from Melanoma Breakthroughs
While Iovance has not released major news this week, investor enthusiasm has been fueled by positive readout data in the advanced skin cancer sector. Recent interim Phase 3 results from Moderna Inc. and Merck & Co. Inc. demonstrated statistically significant improvements in survival metrics for individualized melanoma treatments.
The positive readouts have reinforced market confidence in advanced melanoma therapies, directly benefiting Iovance as it commercializes its own FDA-approved, one-time cell therapy, Amtagvi.
